20-15-2102. Findings.

Arkansas Code — all titles (historical 2020) · legal_authorities

20-15-2102. Findings.

20-15-2102. Findings. It is found and determined by the General Assembly of the State of Arkansas that: (1) The process of approval for investigational drugs, biological products, and devices in the United States often takes many years; (2) Patients who have a terminal disease do not have the luxury of waiting until an investigational drug, biological product, or device receives final approval; (3) The standards of the United States Food and Drug Administration for the use of investigational drugs, biological products, and devices may deny the benefits of potentially life-saving treatments to terminally ill patients; (4) The State of Arkansas recognizes that patients who have a terminal disease have a fundamental right to attempt to pursue the preservation of their own lives by accessing available investigational drugs, biological products, and devices; and (5) The use of available investigational drugs, biological products , or devices is a decision that should be made by the patient with a terminal disease in consultation with his or her physician.

Source: Arkansas Code — historical release 78 (November 6, 2020) · 20-15-2102

Stored review status: Historical 2020-11-06 source release; later amendments not reconciled; machine-extracted, not independently legally reviewed; source heading status: text_in_historical_source. A text match is a research starting point; applicability is not established.